Bladder Urothelial Carcinoma: Correlation between gene mutation status and selected clinical features
(primary solid tumor cohort)
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Overview
Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 7 genes and 6 clinical features across 28 patients, one significant finding detected with Q value < 0.25.

  • KDM6A mutation correlated to 'STOPPEDSMOKINGYEAR'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between mutation status of 7 genes and 6 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, one significant finding detected.

Clinical
Features
Time
to
Death
AGE GENDER NUMBERPACKYEARSSMOKED STOPPEDSMOKINGYEAR TOBACCOSMOKINGHISTORYINDICATOR
nMutated (%) nWild-Type logrank test t-test Fisher's exact test t-test t-test t-test
KDM6A 6 (21%) 22 0.675
(1.00)
0.503
(1.00)
0.634
(1.00)
0.00162
(0.0535)
0.428
(1.00)
TP53 11 (39%) 17 0.825
(1.00)
0.529
(1.00)
1
(1.00)
0.543
(1.00)
0.395
(1.00)
0.78
(1.00)
FBXW7 5 (18%) 23 0.894
(1.00)
0.233
(1.00)
1
(1.00)
0.324
(1.00)
0.31
(1.00)
GPS2 3 (11%) 25 0.803
(1.00)
0.115
(1.00)
1
(1.00)
0.671
(1.00)
NFE2L2 4 (14%) 24 0.647
(1.00)
0.839
(1.00)
0.0103
(0.328)
0.112
(1.00)
HCN1 4 (14%) 24 0.295
(1.00)
0.637
(1.00)
0.601
(1.00)
0.0795
(1.00)
0.815
(1.00)
ARID1A 6 (21%) 22 0.534
(1.00)
0.788
(1.00)
1
(1.00)
0.557
(1.00)
'KDM6A MUTATION STATUS' versus 'STOPPEDSMOKINGYEAR'

P value = 0.00162 (t-test), Q value = 0.054

Table S1.  Gene #2: 'KDM6A MUTATION STATUS' versus Clinical Feature #5: 'STOPPEDSMOKINGYEAR'

nPatients Mean (Std.Dev)
ALL 9 1974.0 (17.2)
KDM6A MUTATED 4 1990.2 (3.9)
KDM6A WILD-TYPE 5 1961.0 (10.3)

Figure S1.  Get High-res Image Gene #2: 'KDM6A MUTATION STATUS' versus Clinical Feature #5: 'STOPPEDSMOKINGYEAR'

Methods & Data
Input
  • Mutation data file = BLCA-TP.mutsig.cluster.txt

  • Clinical data file = BLCA-TP.clin.merged.picked.txt

  • Number of patients = 28

  • Number of significantly mutated genes = 7

  • Number of selected clinical features = 6

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)